Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

Canada NewsWire June 27, 2019

ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

GlobeNewswire June 27, 2019

ProMIS Neurosciences Closing Private Placement

Canada NewsWire June 26, 2019

ProMIS Names Award-Winning Researcher to Advisory Board

Stockhouse Editorial June 19, 2019

ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

Canada NewsWire June 19, 2019

ProMIS to Present Alzheimer’s Program Data at Premier Event

Stockhouse Editorial June 5, 2019

ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

Canada NewsWire June 5, 2019

ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

Canada NewsWire May 29, 2019

PODCAST: Saving Minds Episode 6

Featured Submission May 28, 2019

ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau

Canada NewsWire May 28, 2019

ProMIS Drug Platform Sees Value Expatiated in Q1 2019

Stockhouse Editorial May 14, 2019

ProMIS Neurosciences Announces First Quarter 2019 Results

Canada NewsWire May 14, 2019

ProMIS Neurosciences to Participate in the Think Equity Investor Conference

Canada NewsWire April 23, 2019

Positive Results and New Technology Give Rise to Antibody Dominance

GlobeNewswire March 27, 2019

ProMIS to Present Discoveries at NY Microcap Conference

Stockhouse Editorial March 26, 2019

ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019

Canada NewsWire March 26, 2019

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

Canada NewsWire March 21, 2019

ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference

Canada NewsWire March 19, 2019

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

Canada NewsWire March 15, 2019

Attacking the Right Therapeutic Target in Alzheimer’s Disease

Featured Submission March 4, 2019